rothman vice president clinical development biotech north brunswick New Jersey working -based lovaxin c. pretty nifty bug purpose adds rothman co opting lot evolution modifies immune system lot ways advaxis 2005 2007 15 women progressive recurrent advanced cervical cancer previously treated unsuccessfully chemotherapy radiotherapy surgery women reacted symptoms including headache fever chills rothman attributes body immune response designed fight infection patients generally tolerated lovaxin c depending strength dose given drug cause high fevers significant drops blood pressure response rate survival data encouraging rothman says company announced tuesday expects initiate phase ii lovaxin c testing u.s. summer treatment overgrowth cells cervix caused